GO:0043527 tRNA methyltransferase complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043527 (tRNA methyltransferase complex) is a cellular component defined as a multimeric protein complex that methylates specific nucleotides in tRNA.
• The best-characterized member is the METTL1-WDR4 complex, which installs m7G at tRNA position 46 and requires the obligate cofactor WDR4 for stability and activity.
• Other complexes include the METTL6-SerRS module for m3C at tRNA position 32 and the THUMPD3-TRMT112 complex for m2G at position 6.
• These complexes are deregulated in cancer, where they drive oncogenic transformation, drug resistance, and metabolic plasticity.
• Loss-of-function mutations in complex subunits are linked to human disease, including ovarian insufficiency and neurodevelopmental phenotypes.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect subunit-specific and catalytic-dependent functions.
Description
The tRNA methyltransferase complex (GO:0043527) is a cellular component defined as a multimeric protein complex involved in the methylation of specific nucleotides in tRNA. Rather than acting as isolated enzymes, tRNA methyltransferases typically assemble with obligatory accessory subunits that recognize tRNA substrates, stabilize the catalytic subunit, and regulate modification site specificity. This organization ensures precise and efficient installation of chemical marks such as N7-methylguanosine (m7G), 3-methylcytidine (m3C), and N2-methylguanosine (m2G) at defined positions within the tRNA body. These modifications are not decorative; they influence tRNA folding, stability, codon-anticodon interactions, and translation fidelity. Consequently, the tRNA methyltransferase complex sits at the interface of epitranscriptomics and proteostasis, shaping the cellular proteome in response to growth, stress, and metabolic cues. In cancer, dysregulation of these complexes can reprogram translation to favor oncogenic transcripts, promote drug resistance, and support metastatic dissemination. For researchers, GO:0043527 provides a framework to study how multimeric assemblies coordinate RNA modification. Understanding the composition, assembly, and regulation of these complexes is essential for interpreting how tRNA modifications contribute to normal physiology and disease, and for designing targeted interventions.
tRNA methyltransferase complex At A Glance
| GO ID | GO:0043527 |
|---|---|
| GO term | tRNA methyltransferase complex |
| Ontology | cellular_component |
| Synonym | None |
| Major function | Methylation of specific nucleotides in tRNA |
| Example complex | METTL1-WDR4 (m7G at position 46) |
| Other examples | METTL6-SerRS (m3C at position 32); THUMPD3-TRMT112 (m2G at position 6) |
| Cofactor requirement | S-adenosylmethionine (SAM) as methyl donor |
| Disease relevance | Cancer, ovarian insufficiency, metabolic disorders |
What Is GO:0043527?
GO:0043527 describes a multimeric protein complex that methylates specific nucleotides in tRNA. It is a cellular component term, meaning it refers to a physical assembly of proteins rather than an isolated enzymatic activity. The complex typically contains a catalytic methyltransferase subunit and one or more accessory proteins that are required for substrate recognition, catalytic efficiency, or complex stability.
Why Is tRNA methyltransferase complex Important in Cell Biology?
The tRNA methyltransferase complex is important because it directly controls the chemical modification landscape of tRNA, which in turn regulates translation efficiency and fidelity. By installing modifications such as m7G, m3C, and m2G, these complexes influence tRNA stability, codon decoding, and the translation of specific mRNA subsets, including oncogenes and stress-response factors. Dysregulation of these complexes is increasingly recognized in human disease, making them attractive targets for mechanistic studies and therapeutic development.
• Controls tRNA modification status, which affects tRNA stability and translation fidelity.
• Regulates translation of specific mRNAs, including oncogenes and metabolic regulators.
• Drives oncogenic transformation and cancer progression when overexpressed.
• Mediates resistance to targeted therapies such as lenvatinib in hepatocellular carcinoma.
• Supports metabolic plasticity during metastasis through mitochondrial RNA modifications.
• Links to inherited disease: mutations in complex subunits are associated with ovarian insufficiency.
• Provides a model system for studying multimeric RNA-modifying enzyme assembly.
• Offers potential biomarkers and therapeutic targets in oncology.
• Enables dissection of catalytic versus non-catalytic functions of methyltransferases.
• Connects epitranscriptomics to proteostasis and autophagy.
Structure and Composition of tRNA methyltransferase complex
METTL1-WDR4: The m7G tRNA Methyltransferase Complex
In simple terms: METTL1 is the enzyme that adds a methyl mark to tRNA, and WDR4 is its essential partner that keeps it stable and active.
The METTL1-WDR4 complex is the best-characterized tRNA methyltransferase complex. METTL1 is the catalytic subunit that transfers a methyl group from S-adenosylmethionine to guanosine 46 of tRNA, forming m7G. WDR4 is a WD40-repeat protein that binds METTL1, stabilizes it, and is required for efficient tRNA methylation. Structural studies show that WDR4 forms a scaffold that positions METTL1 for optimal substrate recognition and catalysis. Loss of WDR4 destabilizes METTL1 and abolishes m7G modification, demonstrating that the complex, not the isolated enzyme, is the functional unit.
METTL6-SerRS: The m3C tRNA Methyltransferase Module
In simple terms: METTL6 works together with a seryl-tRNA synthetase to add a methyl mark to tRNA, and the synthetase helps METTL6 find its target.
METTL6 forms a complex with seryl-tRNA synthetase (SerRS) to methylate tRNA at position 32, generating m3C. The crystal structure of the METTL6-SerRS complex reveals how SerRS acts as a tRNA-binding platform that presents the substrate to METTL6. This interaction couples tRNA aminoacylation machinery with RNA modification, suggesting coordination between translation and epitranscriptomic regulation.
THUMPD3-TRMT112: The m2G tRNA Methyltransferase Complex
In simple terms: THUMPD3 and TRMT112 form a two-protein machine that adds a methyl mark to tRNA position 6.
The THUMPD3-TRMT112 complex catalyzes m2G modification at tRNA position 6. THUMPD3 is the catalytic subunit, while TRMT112 serves as an essential activator and stabilizing partner. This complex has been implicated in pancreatic cancer progression and autophagy regulation through modulation of TFEB translation. The THUMPD3-TRMT112 pair exemplifies how obligate heterodimeric assemblies are common among tRNA methyltransferases.
Assembly and Stoichiometry
In simple terms: These complexes are built from two or more proteins that must come together in the right amounts to work properly.
tRNA methyltransferase complexes typically assemble as heterodimers or higher-order multimers. The catalytic subunit requires its accessory partner for stability, and disruption of the partner often leads to degradation of the entire complex. Stoichiometry is critical: overexpression of one subunit without the other can lead to aggregation or loss of function. Structural and biochemical studies have defined the interfaces and conformational changes that accompany complex assembly.
Subcellular Localization
In simple terms: These complexes are found in the main compartment of the cell where tRNA is made and processed.
Most tRNA methyltransferase complexes localize to the nucleus and cytosol, where tRNA maturation and modification occur. Some modifications, such as those in mitochondrial tRNA, are installed by distinct complexes within mitochondria. The subcellular distribution of these complexes can influence which tRNA pools are modified and how cells respond to metabolic stress.
Key Genes Involved in GO:0043527 tRNA methyltransferase complex
The following genes encode subunits and associated factors of tRNA methyltransferase complexes, as supported by structural, biochemical, and functional studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| METTL1 | Catalytic subunit for m7G at tRNA position 46 | Oncogenic transformation, drug resistance |
| WDR4 | Obligate partner stabilizing METTL1 | Required for m7G modification and complex stability |
| METTL6 | Catalytic subunit for m3C at tRNA position 32 | Structural basis of tRNA recognition |
| SerRS (SARS1) | Seryl-tRNA synthetase, presents tRNA to METTL6 | Couples aminoacylation with modification |
| THUMPD3 | Catalytic subunit for m2G at tRNA position 6 | Pancreatic cancer progression, autophagy |
| TRMT112 | Activator and stabilizing partner for THUMPD3 | Essential for m2G modification |
| TRMT6 | Subunit of m1A tRNA methyltransferase complex | tRNA modification and translation |
| TRMT61A | Catalytic subunit for m1A at tRNA position 58 | tRNA modification and translation |
| TRMT10A | Catalytic subunit for m1G at tRNA position 9 | tRNA modification and translation |
| TRMT10C | Mitochondrial tRNA methyltransferase subunit | Mitochondrial RNA modifications in metastasis |
| TRMT5 | Catalytic subunit for m1G at tRNA position 37 | tRNA modification and translation |
| TRMT61B | Mitochondrial m1A methyltransferase | Mitochondrial translation and metabolism |
| NSUN2 | RNA m5C methyltransferase acting on tRNA | tRNA stability and translation |
| NSUN6 | tRNA m5C methyltransferase | tRNA modification and translation |
| ALKBH8 | tRNA hydroxylase/ methyltransferase complex component | tRNA wobble modification |
| FTSJ1 | tRNA 2'-O-methyltransferase | tRNA modification and translation |
| PUS7 | Pseudouridine synthase acting on tRNA | tRNA modification and translation |
How Is tRNA methyltransferase complex Regulated?
The activity and assembly of tRNA methyltransferase complexes are regulated at multiple levels. Expression of catalytic subunits such as METTL1 is controlled by oncogenic signaling and stress-responsive transcription factors, leading to altered m7G levels in cancer. The availability of the methyl donor S-adenosylmethionine (SAM) links complex activity to cellular metabolism. Post-translational modifications and partner protein availability also influence complex stability; for example, WDR4 levels determine METTL1 abundance and activity. In mitochondria, RNA modifications shape metabolic plasticity during metastasis, indicating that nutrient and oxygen status can regulate these complexes. Additionally, the THUMPD3-TRMT112 complex modulates TFEB translation, connecting tRNA methylation to autophagy and lysosomal biogenesis.
tRNA methyltransferase complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| METTL1 | Oncogenic transformation, lenvatinib resistance | Knockout and overexpression in cancer cell lines |
| WDR4 | Complex stability, cancer progression | Knockout and point-mutation models |
| THUMPD3 | Pancreatic cancer progression, autophagy | Knockout and overexpression in pancreatic cancer models |
| TRMT112 | m2G modification, cancer | Knockout and rescue models |
| METTL6 | tRNA m3C modification, translation | Structural and knockout studies |
Cancer and Oncogenic Transformation
Dysregulation of tRNA methyltransferase complexes is a hallmark of multiple cancers. METTL1-mediated m7G modification promotes oncogenic transformation and is required for the translation of growth-promoting mRNAs. In hepatocellular carcinoma, METTL1-WDR4 activity drives resistance to lenvatinib, a first-line targeted therapy. The THUMPD3-TRMT112 complex promotes pancreatic cancer progression and autophagy by modulating TFEB translation. These findings position tRNA methyltransferase complexes as potential therapeutic targets and biomarkers of drug response.
Metabolic Plasticity and Metastasis
Mitochondrial RNA modifications, installed by distinct tRNA methyltransferase complexes, shape metabolic plasticity during metastasis. This suggests that these complexes help cancer cells adapt to metabolic stress and support metastatic colonization. The link between tRNA modification and metabolism highlights the broader role of these complexes beyond translation fidelity.
Ovarian Insufficiency and Reproductive Disorders
Genetics of ovarian insufficiency and defects of folliculogenesis have implicated tRNA modification pathways, including components related to tRNA methyltransferase complexes. Mutations affecting tRNA modification can impair germ cell development and folliculogenesis, leading to premature ovarian insufficiency. This connection underscores the importance of these complexes in reproductive biology.
From tRNA methyltransferase complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of METTL1 abolish m7G and reduce oncogenic translation? | METTL1 knockout cell lines |
| Is the catalytic activity of METTL1 required for transformation? | Catalytically dead point-mutation knock-in |
| Does WDR4 stabilization affect METTL1 function? | WDR4 knockout and tagged knock-in |
| How does THUMPD3-TRMT112 regulate autophagy? | THUMPD3 knockout with TFEB reporter |
| What is the role of METTL6 in tRNA recognition? | METTL6 point mutations based on structure |
| Does overexpression of METTL1 drive drug resistance? | METTL1 overexpression in cancer cells |
How to Study the tRNA methyltransferase complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ribo-seq | Ribosome occupancy and translation efficiency | Assess impact of complex loss on translation |
| m7G-MeRIP | m7G modification levels on tRNA | Validate METTL1-WDR4 activity |
| Mass spectrometry | Nucleotide modification stoichiometry | Quantify m3C, m2G, m7G |
| Cryo-EM | 3D structure of complex and tRNA | Define assembly and substrate recognition |
| Co-immunoprecipitation | Protein-protein interactions | Identify complex subunits |
| CRISPR knockout | Loss-of-function phenotypes | Determine gene essentiality |
| CRISPR knock-in | Tagged or mutant alleles | Study localization and catalytic mutants |
| RNA-seq | Transcriptome changes | Identify downstream pathways |
Ribo-seq and Translation Profiling
Ribo-seq measures ribosome occupancy and translation efficiency. It is used to determine how loss or gain of tRNA methyltransferase complex activity affects global and transcript-specific translation. For example, METTL1 knockout reduces translation of mRNAs enriched in m7G-dependent codons.
RNA Modification Detection
Techniques such as m7G-MeRIP, m3C-specific sequencing, and mass spectrometry quantify tRNA modification levels. These methods confirm the catalytic output of specific complexes and validate knockout or point-mutation models.
Structural Biology
Cryo-EM and X-ray crystallography reveal how subunits assemble and recognize tRNA. Structures of METTL1-WDR4 and METTL6-SerRS have defined the molecular basis of substrate specificity and catalysis.
Proteomics and Interactomics
Affinity purification coupled to mass spectrometry identifies complex components and dynamic interactors. This approach helps discover new subunits and regulatory factors of tRNA methyltransferase complexes.
How CRISPR Can Be Used to Study GO:0043527 tRNA methyltransferase complex
Knockout
CRISPR knockout of catalytic subunits such as METTL1, METTL6, or THUMPD3 abolishes specific tRNA modifications and reveals their cellular functions. Knockout models are used to test whether complex activity is required for proliferation, transformation, or stress responses.
Point Mutation
Catalytically dead point mutations in the methyltransferase domain allow separation of catalytic activity from scaffolding functions. For example, a methyltransferase-independent role for METTL1 in tRNA aminoacylation and oncogenic transformation has been demonstrated using point mutants.
Knock-in
Knock-in of epitope tags or fluorescent reporters enables tracking of complex localization, assembly, and dynamics in live cells. Tagged knock-in of WDR4 or METTL1 can be used for affinity purification and interactome studies.
Overexpression
Overexpression of METTL1 or THUMPD3-TRMT112 is used to model gain-of-function phenotypes observed in cancer, including drug resistance and enhanced translation of oncogenic mRNAs.
How EDITGENE Supports tRNA methyltransferase complex Research
Researchers studying tRNA methyltransferase complex-related genes often need to determine whether a candidate gene is causally involved in tRNA modification, translation control, or disease phenotypes. Rigorous causal inference requires well-controlled genetic models that isolate catalytic activity, complex assembly, and downstream effects. EDITGENE provides end-to-end CRISPR services to generate such models efficiently and reproducibly.
Contact EDITGENE today to design your custom CRISPR model for tRNA methyltransferase complex research.
Frequently Asked Questions About tRNA methyltransferase complex
What is GO:0043527?
GO:0043527 is the Gene Ontology term for tRNA methyltransferase complex, a multimeric protein complex that methylates specific nucleotides in tRNA.
What genes are involved in tRNA methyltransferase complex?
Key genes include METTL1, WDR4, METTL6, SerRS, THUMPD3, and TRMT112, among others.
What does the METTL1-WDR4 complex do?
It installs m7G at tRNA position 46 and regulates translation of specific mRNAs.
How is tRNA methyltransferase complex linked to cancer?
Dysregulation promotes oncogenic transformation, drug resistance, and metabolic plasticity.
What diseases are associated with tRNA methyltransferase complex mutations?
Cancers such as hepatocellular carcinoma and pancreatic cancer, as well as ovarian insufficiency.
How can I study tRNA methyltransferase complex in the lab?
Use CRISPR knockout, point-mutation, knock-in, and overexpression models combined with Ribo-seq and modification detection.
What is the role of WDR4 in the complex?
WDR4 stabilizes METTL1 and is required for m7G modification.
What is m7G tRNA modification?
m7G is N7-methylguanosine, a tRNA modification installed by METTL1-WDR4 that affects translation.
Can tRNA methyltransferase complexes be targeted therapeutically?
They are considered potential targets in cancer, though further validation is needed.
What model systems are best for studying tRNA methyltransferase complex?
Cancer cell lines with CRISPR knockouts and knock-ins, combined with structural and biochemical assays.
Conclusion
The tRNA methyltransferase complex (GO:0043527) is a central node in epitranscriptomic regulation, linking tRNA modification to translation control, metabolism, and disease. Structural and functional studies have defined the composition and mechanisms of major complexes such as METTL1-WDR4, METTL6-SerRS, and THUMPD3-TRMT112. Their dysregulation contributes to cancer progression, drug resistance, and reproductive disorders. Continued research using precise CRISPR models will clarify how these complexes can be targeted for therapeutic benefit.
References
- 1. Ali RH et al.. 2025. A methyltransferase-independent role for METTL1 in tRNA aminoacylation and oncogenic transformation.. Mol Cell 85(5):948-961.e11 PMID: 39892392
- 2. Huang M et al.. 2023. METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma.. Cancer Res 83(1):89-102 PMID: 36102722
- 3. Throll P et al.. 2024. Structural basis of tRNA recognition by the m(3)C RNA methyltransferase METTL6 in complex with SerRS seryl-tRNA synthetase.. Nat Struct Mol Biol 31(10):1614-1624 PMID: 38918637
- 4. Delaunay S et al.. 2022. Mitochondrial RNA modifications shape metabolic plasticity in metastasis.. Nature 607(7919):593-603 PMID: 35768510
- 5. Yuan W et al.. 2026. tRNA m(2)G methyltransferase complex THUMPD3-TRMT112 promotes pancreatic cancer progression and autophagy via modulating TFEB translation.. Mol Cancer 25(1) PMID: 41530782
- 6. Ruiz-Arroyo VM et al.. 2023. Structures and mechanisms of tRNA methylation by METTL1-WDR4.. Nature 613(7943):383-390 PMID: 36599982
- 7. Li J et al.. 2023. Structural basis of regulated m(7)G tRNA modification by METTL1-WDR4.. Nature 613(7943):391-397 PMID: 36599985
- 8. França MM et al.. 2022. Genetics of ovarian insufficiency and defects of folliculogenesis.. Best Pract Res Clin Endocrinol Metab 36(1):101594 PMID: 34794894
